Our biotech industry is working at unprecedented speeds to bring a COVID-19 vaccine to market; rather than unprecedented, these speeds should be the new norm.
What stands between them, their patients, and this information is a world of complexity that includes health insurers, pharmacy benefit managers (PBMs), pharmacies, drug manufacturers, and employers, and the many layers of benefit design, rebates, and …
A study published in this month’s Pediatrics looked at the incidence and risk factors associated with Covid-19 infections in adults caring for children in the early months of the pandemic.
The interim results of the World Health Organization’s Solidarity Therapeutics Trial are in — and they don’t bode well for remdesivir, the antiviral drug that for months was touted as a moderately effective treatment for Covid-19.
Dr. Mark Kortepeter, a physician and biodefense expert who has been involved in combating multiple epidemics, discusses five reasons why wearing masks will continue to be an important infection prevention tool long after the first Covid-19 vaccine.